Patel, S., Thompson, J., Daugherty, F. J., Bidard, F. C., Gradishar, W. J., Martín, M., O'Shaughnessy, J., Rugo, H. S., Santa-Maria, C. A., Schmidt, M., Spring, L., Rimawi, M. (2026). Preliminary injection site reaction immune response results from open-label arm of ongoing phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy (Flamingo-01).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba538